

Attorney's Docket No. 049542/303320

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Wilson *et al.* Confirmation No.: 2081
Appl. No.: 10/560,853 Group Art Unit: 1624
Filed: 12/8/05
For: A₁ ADENOSINE RECEPTOR ANTAGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTION OF PUBLICATION

Sir:

In reviewing Publication No. US2007/0274910 published November 29, 2007, for the above-referenced application, Applicant notes an error on page 14 of the publication. A portion of Claim 22 has been omitted. Copies of pages 8 and 9 of the Preliminary Amendment submitted on December 8, 2005 are attached indicating the correct format for Claim 22.

It is respectfully requested that this error be corrected and that page 14 of the publication be republished.

Respectfully submitted,

/michelle l. cunningham/
Michelle L. Cunningham
Registration No. 51,072

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON JANUARY 2, 2008

LEGAL02/30651900v1

~~salts, solvates, and hydrates thereof~~ wherein at least one of its atoms or one or more atoms bonded thereto are radioactively radioactive, spin labeled, or both radioactively radioactive and spin labeled.


18. (Original) The imaging agent of according to Claim 17 wherein the marker atom is a nuclear spin labeled.

19. (Original) The imaging agent of according to Claim 18 wherein the marker atom is a ^{19}F .

20. (Original) The imaging agent of according to Claim 17 wherein the marker atom is a radioactive isotope.

21. (Original) The imaging agent of according to Claim 17 wherein the radioactive isotope is ^{18}F , ^{11}C , ^{15}N , ^{125}I , or ^{3}H


22. (Currently amended) A method of treating A₁ adenosine receptor related disorders in a mammal in need of treatment thereof, comprising administering an effective amount of a compound according to claim 1, of formula (I):



wherein

R_1 is a branched or straight chain $\text{C}_4\text{--C}_8$ alkyl;


R_2 is of the formula (II),



wherein n is an integer ranging from 1 to 8; R_5 is H or $(CH_2)_p CH_3$, and R_6 is H or $(CH_2)_m OH$,

wherein p is an integer ranging from 1 to 7 and m is an integer ranging from 1 to 8;


R_3 is of the formula (III),



wherein q is an integer ranging from 1 to 8; and R_7 is selected from the group consisting of H, OH, NH_2 , $(CH_2)_t OH$, and $R_9 COOH$;

wherein R_9 is a straight or branched chain alkylene or alkenylene group having 1 to 8 carbon atoms, and t is an integer ranging from 1 to 8;

R_4 is of the formula (IV),



wherein r is an integer ranging from 1 to 8 and R_8 is selected from the group consisting of H, OH, $(CH_2)_f NH_2$, $(CH_2)_s OH$, and $R_{10} COOH$

wherein f is 0 or f and s are independently integers ranging from 1 to 8; and,

R_{10} is a C_1-C_8 straight or branched chain alkylene or alkenylene; and; or a pharmaceutically acceptable salt salts, solvate solvates, or hydrate and hydrates thereof, or a combination of compounds according to claim 1 of formula (I), optionally in combination with one or more other therapeutic agents, to the mammal in need thereof.